Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

US biotech Novavax (Nasdaq: NVAX) has reported that its experimental combination COVID-19 and influenza vaccine generated ...

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental ...

Cheng Xin / Getty Images Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine. The shot, Nuvaxovid, is designed for older adults and those between the ...

Novavax, Inc. (NVAX) on Wednesday said that its COVID-19-Influenza combination and stand-alone Influenza vaccine candidates ...

non-mRNA COVID-19 vaccine,” said John C. Jacobs, President and Chief Executive Officer, Novavax. Along with the approval, the FDA also requested Novavax conduct a phase 4 randomized, double ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...